Spyre Therapeutics
SYRE----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Spyre Therapeutics(SYRE) predict that the EBIT is -45.64 M (+14.8%), Beat estimate;the EPS is -0.74 (-23.33%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.05B14.80%
-0.06B13.51%
+0.02B28.31%
EPSMiss expectations
-0.7423.33%
-0.685414.23%
-0.05469.10%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf